Deep Track Capital’s Intellia Therapeutics NTLA Stock Holding History

Deep Track Capital’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,950,000	Closed	-$102M	–	74
2024 Q3	$102M	Buy	4,950,000 +150,000	+3%	+$3.46M	3.23%	10
2024 Q2	$107M	Buy	4,800,000 +589,216	+14%	+$14M	3.21%	10
2024 Q1	$116M	Buy	4,210,784 +1,960,784	+87%	+$54.5M	3.32%	9
2023 Q4	$68.6M	Buy	2,250,000 +250,000	+13%	+$7.18M	2.29%	14
2023 Q3	$63.2M	Buy	2,000,000 +1,164,554	+139%	+$45.2M	2.44%	15
2023 Q2	$34.1M	Buy	835,446 +130,913	+19%	+$5.31M	1.58%	20
2023 Q1	$26.3M	Buy	704,533 +4,533	+0.6%	+$178K	1.08%	33
2022 Q4	$24.4M	Buy	700,000 +400,000	+133%	+$19M	1.03%	37
2022 Q3	$16.8M	Buy	+300,000	New	+$18.6M	0.77%	46

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deep Track Capital's NTLA Position: Q4 2024 in Review

Deep Track Capital sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 4,950,000 shares — an estimated $102M sold.

Deep Track Capital first reported a position in NTLA in Q3 2022 and held it in 9 quarters. The position peaked at $116M in Q1 2024. 294 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

Deep Track Capital reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
Deep Track Capital sold 4,950,000 Intellia Therapeutics shares in Q4 2024, an estimated $102M.
Deep Track Capital first reported a position in Intellia Therapeutics in Q3 2022 and held it in 9 quarters.
Deep Track Capital's Intellia Therapeutics position peaked at $116M in Q1 2024.
294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Deep Track Capital's 13F filing for Q4 2024, filed 14 Feb 2025.